Results 131 to 140 of about 4,608 (197)

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies [PDF]

, 2015
Sander Bison, Joost Haeck, Karin Bol, Stuart Koelewijn, Harald C. Groen, Marleen Melis, Jifke F. Veenland, Monique R. Bernsen, Marion de Jong   +8 more
openalex   +1 more source

Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology. [PDF]

Diagnostics (Basel)
Sabuzi F, Filippi L, Trulli M, Domenici F, Garaci F, Da Ros V.   +5 more
europepmc   +1 more source

Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review. [PDF]

Front Endocrinol (Lausanne)
Kuhlen M, Claus R, Pavel ME, Kunstreich M, Begum N, Lapa C, Redlich A.   +6 more
europepmc   +1 more source

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors. [PDF]

Eur J Nucl Med Mol Imaging
di Santo G, Santo G, Wirth L, Kronthaler A, Gastl G, Djanani A, Virgolini IJ.   +6 more
europepmc   +1 more source

A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology [PDF]

Valentina Vasić, Johan Gustafsson, Elham Yousefzadeh Nowshahr, Anna Stenvall, Ambros J. Beer, Katarina Sjögreen Gleisner, Gerhard Glatting   +6 more
openalex   +1 more source

¹⁷⁷Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Wang J, Pang X, Lian J, Lu H.
europepmc   +1 more source

The SCARLET Trial: Radiotheranostics in Multiple Myeloma. [PDF]

Radiol Imaging Cancer
Jain S, Graham MM.
europepmc   +1 more source

Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study [PDF]

Iness Megherbi, Christopher Hoog, Marine Perrier, Hédia Brixi, Guillaume Cadiot, Christine Hoeffel-Fornes, David Morland   +6 more
openalex   +1 more source